Here, we present a case with TFG::ROS1 fusion and highlight the significance of molecular tumor boards (MTBs) in clinical precision oncology for post-last-line therapy.<h4>Case presentation</h4>A 32-year-old woman presented with IMT diagnosed at age 27 for biopsy and treatment evaluation. This evidence concerns the gene TFG and inflammatory myofibroblastic tumor.